Source: Geron Corporation
Date: November 11, 2010
Summary:
Geron Corporation today announced today announced the publication of preclinical data demonstrating that the company's telomerase inhibitor drug, imetelstat (GRN163L), currently in Phase 2 clinical trials, targets cancer stem cells from multiple myeloma, pancreatic and breast cancers.
The first publication shows the inhibitory effect of imetelstat on multiple myeloma cancer stem cells in vitro and in animal models of the human disease. The research was co-authored by Dr. William Matsui and colleagues at The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins and scientists from Geron and is published in the journal PLoS ONE.
The second publication demonstrates the inhibitory effect of imetelstat on cancer stem cells from breast and pancreatic tumor cell lines in vitro and in animal models of the human disease. The data, published in the journal Cancer Research.
